Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEFPODOXIME PROXETIL Cause Bladder transitional cell carcinoma? 21 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Bladder transitional cell carcinoma have been filed in association with CEFPODOXIME PROXETIL (Cefpodoxime Proxetil). This represents 6.5% of all adverse event reports for CEFPODOXIME PROXETIL.

21
Reports of Bladder transitional cell carcinoma with CEFPODOXIME PROXETIL
6.5%
of all CEFPODOXIME PROXETIL reports
0
Deaths
21
Hospitalizations

How Dangerous Is Bladder transitional cell carcinoma From CEFPODOXIME PROXETIL?

Of the 21 reports, 21 (100.0%) required hospitalization.

Is Bladder transitional cell carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEFPODOXIME PROXETIL. However, 21 reports have been filed with the FAERS database.

What Other Side Effects Does CEFPODOXIME PROXETIL Cause?

Drug hypersensitivity (48) Diarrhoea (26) Dizziness (23) Pyrexia (22) Vomiting (20) Nausea (19) Headache (15) Rash (15) Drug ineffective (14) Abdominal pain (13)

What Other Drugs Cause Bladder transitional cell carcinoma?

PIOGLITAZONE (398) ADALIMUMAB (96) METHOTREXATE (95) RITUXIMAB (74) TOCILIZUMAB (68) INFLIXIMAB (63) SULFASALAZINE (55) HYDROXYCHLOROQUINE (50) PREDNISONE (48) LENALIDOMIDE (42)

Which CEFPODOXIME PROXETIL Alternatives Have Lower Bladder transitional cell carcinoma Risk?

CEFPODOXIME PROXETIL vs CEFPROZIL CEFPODOXIME PROXETIL vs CEFTAROLINE CEFPODOXIME PROXETIL vs CEFTAROLINE FOSAMIL CEFPODOXIME PROXETIL vs CEFTAZIDIME CEFPODOXIME PROXETIL vs CEFTIBUTEN

Related Pages

CEFPODOXIME PROXETIL Full Profile All Bladder transitional cell carcinoma Reports All Drugs Causing Bladder transitional cell carcinoma CEFPODOXIME PROXETIL Demographics